Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QAR3 | ISIN: US0044685008 | Ticker-Symbol: SP4P
Tradegate
15.05.25 | 09:31
2,240 Euro
+0,45 % +0,010
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ACHIEVE LIFE SCIENCES INC Chart 1 Jahr
5-Tage-Chart
ACHIEVE LIFE SCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,3252,38519:53
2,3252,38519:50

Aktuelle News zur ACHIEVE LIFE SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiAchieve Life Sciences targets NDA submission for cytisinicline in June 2025 as open label study hits key milestones3
ACHIEVE LIFE SCIENCES Aktie jetzt für 0€ handeln
DiAchieve Life Sciences Inc. Q1 Loss Increases In Line With Estimates2
DiACHIEVE LIFE SCIENCES, INC. - 10-Q, Quarterly Report1
DiAchieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program101Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May...
► Artikel lesen
DiAchieve Life Sciences GAAP EPS of -$0.37 in-line1
DiACHIEVE LIFE SCIENCES, INC. - 8-K, Current Report-
MoWhat to Expect from Achieve Life Sciences' Earnings1
MoAchieve Life Sciences Q1 2025 Earnings Preview2
21.04.Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine700ORCA-3 Demonstrated a Significant Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo Cytisinicline New Drug Application (NDA) Submission...
► Artikel lesen
21.03.Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory4
12.03.Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q4 2024 Earnings Call Transcript3
11.03.Achieve Life Sciences GAAP EPS of -$0.36 misses by $0.033
11.03.ACHIEVE LIFE SCIENCES, INC. - 10-K, Annual Report3
11.03.Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program180Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British...
► Artikel lesen
11.03.ACHIEVE LIFE SCIENCES, INC. - 8-K, Current Report1
18.02.Here are Rogue Funds Updates on Achieve Life Sciences (ACHV)4
11.02.Achieve Life Sciences announces positive outcome of DSMC review for ORCA-OL cytisinicline clinical trial required for NDA submission (POSITIVE)9
10.02.ACHIEVE LIFE SCIENCES, INC. - 8-K, Current Report-
10.02.Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial2
24.01.Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory16
Seite:  Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2